The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis

European Journal of Pharmacology

Volumn 581, Issue 3, 2008, Pages 315-323

  Horváth, Krisztina ^a   Varga, Csaba ^a   Berkó, Anikó ^a   Pósa, Anikó ^a   László, Ferenc ^a,b   Whittle, Brendan J R ^c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5 Aminosalicylic acid (5 ASA); Aminosalicylates; Heme oxygenase 1 (HO 1); Inflammatory bowel diseases; Mesalamine; Model of colitis; TNBS colitis; Trinitrobenzene sulphonic acid; Zinc protoporphyrin (ZnPP)

Indexed keywords

BIOLOGICAL MARKER; HEME OXYGENASE 1; MESALAZINE; MYELOPEROXIDASE; PROTOPORPHYRIN ZINC; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENTERITIS; ENZYME ACTIVITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BLOTTING, WESTERN; COLITIS; DISEASE MODELS, ANIMAL; HEME OXYGENASE-1; MALE; MESALAMINE; PEROXIDASE; PROTOPORPHYRINS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 38949193198     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.12.004     Document Type: Article

References (48)

1. Ahnfelt-Ronne I., Nielsen O.H., Christensen A., Langholz E., Binder V., and Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98 (1990) 1162-1169
2. Allgayer H., Hofer P., Schmidt M., Bohne P., Kruis W., and Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem. Pharmacol. 43 (1992) 259-262
3. Appleton S.D., Chretien M.L., McLaughlin B.E., Vreman H.J., Stevenson D.K., Brien J.F., Nakatsu K., Maurice D.H., and Marks G.S. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. Drug Metab. Dispos. 27 (1999) 1214-1219
4. Aruoma O.I., Wasil M., Halliwell B., Hoey B.M., and Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem. Pharmacol. 36 (1987) 3739-3742
5. Barton S.G., Rampton D.S., Winrow V.R., Domizio P., and Feakins R.M. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 8 (2003) 329-334
6. Berberat P.O., Yi A.R., Yamashita K., Warny M.M., Csizmadia E., Robson S.C., and Bach F.H. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm. Bowel Dis. 11 (2005) 350-359
7. Boughton-Smith N.K., Wallace J.L., and Whittle B.J.R. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions 25 (1988) 115-123
8. Cavicchi M., Gibbs L., and Whittle B.J.R. Heme oxygenase-1 (HO-1) induction in human intestinal epithelial cells by sulphasalazine and 5-aminosalicylic acid: a potential therapeutic mechanism. Gastroenterology 118 (2000) A804
9. Dijkstra G., Blokzijl H., Bok L., Homan M., van Goor H., Faber K.N., Jansen P.L., and Moshage H. Opposite effect of oxidative stress on inducible nitric oxide synthase and haem oxygenase-1 expression in intestinal inflammation: anti-inflammatory effect of carbon monoxide. J. Pathol. 204 (2004) 296-303
10. Dryden Jr. G.W., Deaciuc I., Arteel G., and McClain C.J. Clinical implications of oxidative stress and antioxidant therapy. Curr. Gastroenterol. Rep. 7 (2005) 308-316
11. Egan L.J., Mays D.C., Huntoon C.J., Bell M.P., Pike M.G., Sandborn W.J., Lipsky J.J., and McKean D.J. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem. 274 (1999) 26448-26453
12. Foresti R., Green C.J., and Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem. Soc. Symp. 71 (2004) 177-192
13. Freitas A., Alves-Filho J.C., Secco D.D., Neto A.F., Ferreira S.H., Barja-Fidalgo C., and Cunha F.Q. Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br. J. Pharmacol. 149 (2006) 345-354
14. Galvez J., Garrido M., Merlos M., Torres M.I., and Zarzuelo A. Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. Br. J. Pharmacol. 130 (2000) 1949-1959
15. Galvez J., Garrido M., Rodriguez-Cabezas M.E., Ramis I., de Medina F.S., Merlos M., and Zarzuelo A. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm. Bowel Dis. 9 (2003) 363-371
16. Gibbons S.J., and Farrugia G. The role of carbon monoxide in the gastrointestinal tract. J. Physiol. 556 (2004) 325-326
17. Grisham M.B., MacDermott R.P., and Deitch E.A. Oxidant defense mechanisms in the human colon. Inflammation 14 (1990) 669-680
18. Hawkey C.J., Boughton-Smith N.K., and Whittle B.J.R. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig. Dis. Sci. 30 (1985) 1161-1165
19. Hegazi R.A., Rao K.N., Mayle A., Sepulveda A.R., Otterbein L.E., and Plevy S.E. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J. Exp. Med. 202 (2005) 1703-1713
20. Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T., Lyne A., Stephenson D., Palmen M., and Joseph R.E. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007) 66-75
21. Kirkby K.A., and Adin C.A. Products of heme oxygenase and their potential therapeutic applications. Am. J. Physiol. 290 (2006) F563-F571
22. Maines M.D. The heme oxygenase system: update 2005. Antioxid. Redox. Signal. 7 (2005) 1761-1766
23. MacDermott R.P., Schloemann S.R., Bertovich M.J., Nash G.S., Peters M., and Stenson W.F. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology 96 (1989) 442-448
24. McKenzie S.J., Baker M.S., Buffinton G.D., and Doe W.F. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J. Clin. Invest. 98 (1996) 136-141
25. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., and Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
26. Nielsen O.H., Verspaget H.W., and Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment. Pharmacol. Ther. 2 (1988) 203-211
27. Otterbein L.E., Bach F.H., Alam J., Soares M., Tao Lu H., Wysk M., Davis R.J., Flavell R.A., and Choi A.M. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6 (2000) 422-428
28. Paul G., Bataille F., Obermeier F., Bock J., Klebl F., Strauch U., Lochbaum D., Rummele P., Farkas S., Scholmerich J., Fleck M., Rogler G., and Herfarth H. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin. Exp. Immunol. 140 (2005) 547-555
29. Pavlick K.P., Laroux F.S., Fuseler J., Wolf R.E., Gray L., Hoffman J., and Grisham M.B. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Rad. Biol. Med. 33 (2002) 311-322
30. Qureshi A.I., and Cohen R.D. Mesalamine delivery systems: do they really make much difference? Adv. Drug. Deliv. Rev. 57 (2005) 281-302
31. Reifen R., Nissenkorn A., Matas Z., and Bujanover Y. 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J. Gastroenterol. 39 (2004) 514-519
32. Rivera E., Flores I., Rivera E., and Appleyard C.B. Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm. Bowel Dis. 12 (2006) 950-966
33. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G.C., Chavatte P., Farce A., Bulois P., Cortot A., Colombel J.F., and Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 201 (2005) 1205-1215
34. Ryter S.W., Alam J., and Choi A.M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86 (2006) 583-650
35. Sanchez-Hidalgo M., Martin A.R., Villegas I., Alarcon De, and La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 69 (2005) 1733-1744
36. Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 17 (2003) 29-42
37. Simmonds N.J., Millar A.D., Blake D.R., and Rampton D.S. Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies. Aliment. Pharmacol. Ther. 13 (1999) 363-372
38. Song M., Xia B., and Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad. Med. J. 82 (2006) 130-135
39. Sun F.F., Lai P.S., Yue G., Yin K., Nagele R.G., Tong D.M., Krzesicki R.F., Chin J.E., and Wong P.Y. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation 25 (2001) 33-45
40. Takagi T., Naito Y., Tsuboi H., Isozaki Y., Katada K., Suzuki T., Terao K., Handa O., Kokura S., Ichikawa H., Yoshida N., Okuyama Y., Yagi N., Ueda H., and Yoshikawa T. Increased intestinal luminal carbon monoxide gas in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 24 Suppl 4 (2006) 233-238
41. Tozaki H., Odoriba T., Okada N., Fujita T., Terabe A., Suzuki T., Okabe S., Muranishi S., and Yamamoto A. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control Release 82 (2002) 51-61
42. Urquhart P., Rosignoli G., Cooper D., Motterlini R., and Perretti M. Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J. Pharmacol. Exp. Ther. 321 (2007) 656-662
43. van Bodegraven A.A., and Mulder C.J. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?. World J. Gastroenterol. 12 (2006) 6115-6123
44. Varga C., Laszlo F., Fritz P., Cavicchi M., Lamarque D., Horvath K., Posa A., Berko A., and Whittle B.J.R. Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. Eur. J. Pharmacol. 561 (2007) 164-171
45. Wang W.P., Guo X., Koo M.W., Wong B.C., Lam S.K., Ye Y.N., and Cho C.H. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am. J. Physiol. 281 (2001) G586-G594
46. Whittle B.J.R., Cavicchi M., and Lamarque D. Assessment of anticolitic drugs in the trinitrobenzene sulfonic acid (TNBS) rat model of inflammatory bowel disease. In: Winyard P., and Willoughby D. (Eds). Inflammation Protocols. Methods In Molecular Biology vol. 225 (2003), Humana Press, New Jersey 209-222
47. Willis D., Moore A.R., and Willoughby D.A. Heme oxygenase isoform expression in cellular and antibody-mediated models of acute inflammation in the rat. J. Pathol. 190 (2000) 627-634
48. Wu L., and Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol. Rev. 57 (2005) 585-630